LNWWM
WST icon

Laird Norton Wetherby Wealth Management’s West Pharmaceutical WST Stock Holding History

Laird Norton Wetherby Wealth Management’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$644K Buy
2,454
+10
+0.4% +$2.43K 0.03% 488
2025
Q2 		$535K Buy
+2,444
New +$522K 0.02% 534
2024
Q4 		$1.03M Buy
3,135
+21
+0.7% +$6.61K 0.05% 333
2024
Q3 		$935K Sell
3,114
-126
-4% -$38.6K 0.04% 378
2024
Q2 		$1.07M Sell
3,240
-58
-2% -$20.5K 0.05% 335
2024
Q1 		$1.31M Sell
3,298
-53
-2% -$19.6K 0.06% 299
2023
Q4 		$1.18M Buy
3,351
+9
+0.3% +$3.19K 0.06% 317
2023
Q3 		$1.25M Buy
3,342
+6
+0.2% +$2.32K 0.07% 286
2023
Q2 		$1.28M Sell
3,336
-15
-0.4% -$5.36K 0.07% 287
2023
Q1 		$1.16M Buy
3,351
+183
+6% +$53.5K 0.07% 304
2022
Q4 		$746K Buy
3,168
+381
+14% +$90.3K 0.05% 393
2022
Q3 		$686K Sell
2,787
-341
-11% -$104K 0.05% 384
2022
Q2 		$946K Buy
3,128
+2,306
+281% +$750K 0.06% 309
2022
Q1 		$338K Buy
822
+44
+6% +$17.2K 0.02% 674
2021
Q4 		$365K Buy
778
+109
+16% +$46.9K 0.02% 645
2021
Q3 		$284K Buy
669
+26
+4% +$11K 0.02% 728
2021
Q2 		$231K Buy
+643
New +$212K 0.01% 811
2020
Q1 		– Sell
-2,272
Closed -$342K – 754
2019
Q4 		$342K Buy
2,272
+79
+4% +$11.5K 0.03% 500
2019
Q3 		$311K Sell
2,193
-40
-2% -$5.51K 0.03% 536
2019
Q2 		$279K Hold
2,233
– – 0.03% 564
2019
Q1 		$246K Sell
2,233
-15
-0.7% -$1.56K 0.03% 566
2018
Q4 		$220K Hold
2,248
– – 0.03% 560
2018
Q3 		$278K Hold
2,248
– – 0.03% 516
2018
Q2 		$223K Buy
+2,248
New +$207K 0.03% 571
2018
Q1 		– Sell
-2,082
Closed -$205K – 695
2017
Q4 		$205K Hold
2,082
– – 0.03% 596
2017
Q3 		$200K Buy
+2,082
New +$188K 0.03% 576

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $40.7B AUM 39.97% 1-Year Est. Return

Laird Norton Wetherby Wealth Management's WST Position: Q3 2025 in Review

Laird Norton Wetherby Wealth Management increased its West Pharmaceutical (WST) stake by 0.41% in Q3 2025, buying an estimated $2.43K and bringing the position to 2,454 shares worth $644K. The position accounts for 0.03% of the portfolio, ranked #488.

Laird Norton Wetherby Wealth Management first reported a position in WST in Q3 2017 and has held it in 26 quarters since. The position peaked at $1.31M in Q1 2024. 758 funds tracked by Wall St. Rank hold WST as of Q3 2025.

  • Laird Norton Wetherby Wealth Management held 2,454 shares of West Pharmaceutical worth $644K as of Q3 2025.
  • Laird Norton Wetherby Wealth Management bought 10 West Pharmaceutical shares in Q3 2025, an estimated $2.43K.
  • West Pharmaceutical made up 0.03% of Laird Norton Wetherby Wealth Management's portfolio in Q3 2025, its #488 holding.
  • Laird Norton Wetherby Wealth Management first reported a position in West Pharmaceutical in Q3 2017 and has held it in 26 quarters since.
  • Laird Norton Wetherby Wealth Management's West Pharmaceutical position peaked at $1.31M in Q1 2024.
  • 758 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2025.

Based on Laird Norton Wetherby Wealth Management's 13F filing for Q3 2025, filed 14 Nov 2025.